Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036777 | 0.93 | L3MBTL1 (0.37) | WDR5L3MBTL1TNFALDH1A1GAA | |
| SCHEMBL25622879 | 0.93 | L3MBTL1 (0.37) | WDR5L3MBTL1TNFALDH1A1GAA | |
| SCHEMBL25753602 | 0.93 | L3MBTL1 (0.37) | WDR5L3MBTL1TNFALDH1A1GAA | |
| SCHEMBL28066994 | 0.91 | CNR1 (0.33) | ALDH1A1MAPTKCNA5 | |
| SCHEMBL24036879 | 0.88 | WDR5 (0.32) | WDR5L3MBTL1TNFALDH1A1GAA | |
| SCHEMBL25753606 | 0.87 | MEN1 (0.32) | WDR5L3MBTL1TNFKCNA5 | |
| SCHEMBL25752822 | 0.87 | MEN1 (0.32) | WDR5L3MBTL1TNFKCNA5 | |
| SCHEMBL30389268 | 0.87 | MEN1 (0.32) | WDR5L3MBTL1TNFKCNA5 | |
| SCHEMBL30388831 | 0.85 | SLC13A3 (0.35) | WDR5CTSAMAPT | |
| SCHEMBL25753540 | 0.85 | SLC13A3 (0.35) | WDR5CTSAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | WDR5 2145/4885L3MBTL1 2036/4885TNF 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.